Names and pronunciation
(al-byoo′ter-ole) Airomir , ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin Diskus , Ventolin Nebules , Ventolin HFA
Source page 42
Loading InternPractice…
Individual generic drug information
Extracted information for albuterol only.
(al-byoo′ter-ole) Airomir , ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin Diskus , Ventolin Nebules , Ventolin HFA
Source page 42
Func. class.: Bronchodilator
Source page 42
Chem. class.: Adrenergic β2-agonist, sympathomimetic, bronchodilator
Source page 42
Do not confuse: albuterol/atenolol/Albutein Proventil/Prinivil
Source page 42
ACTION: Causes bronchodilation by action on β2 (pulmonary) receptors by increasing levels of cAMP
Source page 42
USES: Prevention of exercise-induced asthma, acute bronchospasm, bronchitis, emphysema, bronchiectasis, or other reversible airway obstruction
Source page 42
Unlabeled uses: Hyperkalemia in dialy- sis patients, COPD, emphysema
Source page 42
Extracted information for albuterol only.
CONTRAINDICATIONS: Hyper- sensitivity to sympathomimetics Precautions: Pregnancy, breastfeeding, cardiac/renal disease, hyperthyroidism, diabetes mellitus, hypertension, prostatic hypertrophy, angle-closure glaucoma, seizures, exercise-induced broncho- spasm (aerosol) in children <12 yr, hypoglycemia, tachydysrhythmias, severe cardiac disease, heart block
Source page 42
SIDE EFFECTS CNS: Tremors, anxiety, insomnia, head- ache, stimulation, restlessness CV: Angina, hypo/hypertension, dys- rhythmias, chest pain EENT: Dry nose, irritation of nose and throat GI: Nausea, vomiting MISC: Hyperglycemia RESP: Paradoxical bronchospasm
Source page 43
INTERACTIONS Increase: digoxin level—digoxin Increase: CNS stimulation—CNS stimulants Increase: ECG changes/hypokalemia— potassium-losing diuretics Increase: severe hypotension—oxytocics Increase: toxicity—theophylline Increase: action of aerosol bronchodila- tors Increase: action of albuterol—tricyclics, MAOIs, other adrenergics; avoid use together Increase: CV effects—atomoxetine, sele- giline Decrease: albuterol—other β-blockers Drug/Herb Increase: stimulation—caffeine (cola nut, green/black tea, guarana, yerba maté, coffee, chocolate) Drug/Lab Test Decrease: potassium
Source page 44
TREATMENT OF OVERDOSE: Administer β1-adrenergic blocker, IV fluids
Source page 44
Extracted information for albuterol only.
DOSAGE AND ROUTES Bronchospasm prophylaxis/ treatment • Adult and child ≥4 yr: INH (metered- dose inhaler) 2 puffs (180 mcg) q4-6hr as needed; >12 yr INH (powdered in- haler) (ProAir RespiClick) 180 mcg (2 INH) q4-6hr as needed • Adult and child ≥13 yr: PO (ext rel) 4-8 mg q12hr, max 32 mg/day; PO (regu- lar release) 2-4 mg tid, max 32 mg/day • Child 6-12 yr: PO (extended release) 4 mg q12hr, max 24 mg/day; PO (regular release) 6-13 yr 2 mg tid-qid, max 24 mg/day • Child 2-5 yr: PO 0.1 mg/kg tid, max 12 mg/day • Adult and child ≥15 yr: PO (syrup) 2-4 mg tid-qid, max 32 mg/day • Child 6-14 yr: PO (syrup) 2 mg tid- qid, max 24 mg/day • Child 2-5 yr: PO (syrup) 0.1 mg/kg tid, max 12 mg/day Asthma (unlabeled) • Child <4 yr: INH (metered-dose in- haler) 180-600 mcg q2 min, max 6 doses; persistent asthma 2 puffs (HFA) q4-6hr To prevent exercise-induced broncho spasm (not ProAir RespiClick) • Adult/child ≥4 yr: INH 2 puffs before exercise, max 12 puffs/24 hr • Adult/child ≥12 yr: INH (ProAir RespiClick) 2 puffs 15-30 min prior to exercise Other respiratory conditions • Adult and child ≥12 yr: INH (metered- dose inhaler) 1 puff q4-6hr; PO 2-4 mg tid-qid, max 32 mg; NEB/IPPB 2.5 mg tid-qid • Geriatric: PO 2 mg tid-qid, may in- crease gradually to 8 mg tid-qid • Child 2-12 yr: INH (metered-dose in- haler) 0.1 mg/kg tid (max 2.5 mg tid- qid); NEB/IPPB 0.1-0.15 mg/kg/dose tid-qid or 1.25 mg tid-qid for child 10-15 kg or 2.5 mg tid-qid for child >15 kg Hyperkalemia (unlabeled) • Adult: ORAL INH (albuterol nebu- lizer solution) 10-20 mg over 15 min
Source pages 42, 43
Available forms: INH aerosol 100 mcg/ , INH powder 108 mcg/actua- actuation tion; syrup 2 mg/5 mL; tablets 2, 4 mg; ext rel 4, 8 mg; INH sol 0.63 mg/3 mL, 1.25 , 1 mg/3 mL; 2.5 mg/3 mL, 0.5 mg/mL , 2 mg/mL , 5 mg/1 mL mg/mL
Source page 43
Administer: • Store in light-resistant container; do not expose to temperatures of more than 86°F (30°C) PO route A • Do not break, crush, or chew extended-release tablets; give with meals to decrease gastric irritation • Oral solution to children (no alcohol, sugar) Inhalation route • For geriatric patients and children, a spacing device is advised • After shaking metered-dose inhaler, exhale, place mouthpiece in mouth, in- hale slowly while depressing inhaler, hold breath, remove, exhale slowly; give INH at least 1 min apart • NEB/IPPB dilute 5 mg/mL solution/2.5 mL 0.9% NaCl for INH; other solutions do not require dilution; for NEB O2 flow or compressed air 6-10 L/min, 1 treatment lasts 10 min; IPPB 5-20 min ProAir Respistick: • Prior to using for the first time, check that the number “200” is show- ing. Do not wash or put any part of the inhaler in water; if the mouthpiece needs cleaning, wipe with a dry cloth or tissue; when there are “20” doses left, the counter will change to red; refill
Source page 43
Extracted information for albuterol only.
Assess: • Respiratory function: vital capacity, pulse oximetry, forced expiratory vol- ume, ABGs, VBGs; lung sounds, heart rate and rhythm, B/P, sputum (baseline and peak); whether patient has received theophylline therapy before giving dose • Patient’s ability to self-medicate • Trouble breathing with wheezing, hold medication, notify prescriber if broncho- spasm occurs • Pregnancy/breastfeeding: identify if pregnancy is planned or suspected; use only if necessary; avoid breastfeeding
Source page 44
Evaluate: • Therapeutic response: absence of dys- pnea, wheezing; improved airway ex- change; improved ABGs, VBGs
Source page 44
CLINICAL CONSIDERATIONS
Source page 44
Patient and caregiver information: • To use exactly as prescribed; to take missed dose when remembered, alter dosing schedule; not to use OTC medica- tions; that excess stimulation may occur, to use this product before other medica- tions, allow 5 min between each • About use of inhaler: review package insert with patient; use demonstration, return demonstration; shake, prime before first use and when not used for >2 wk; release 4 test sprays into air, away from the face; about when empty and when to renew, a bad taste may occur • To avoid getting aerosol in eyes (blur- ring of vision may result) or use near flames or sources of heat • Do not wash inhaler, wipe with dry cloth, to discard product when counter changes to red • To avoid smoking, smoke-filled rooms, persons with respiratory infections • That paradoxical bronchospasm may occur; to stop product immediately, call prescriber, usually from first dose of new inhaler • To limit caffeine products such as chocolate, coffee, tea, colas • Pregnancy/breastfeeding: to advise prescriber if pregnancy is planned or suspected, or if breastfeeding • To notify health care professional im- mediately if product does not relieve symptoms, corticosteroids may be needed
Source page 44
Extracted information for albuterol only.
PHARMACOKINETICS Extensively metabolized in the liver and tissues, crosses placenta, breast milk, blood-brain barrier, half-life 2.7-6 hr, well absorbed PO: Onset ½ hr, peak 2-3 hr, duration 4-6 hr PO-ER: Onset ½ hr, peak 2-3 hr, dura- tion 8-12 hr INH: Onset 5-15 min, peak 1.5-2 hr, duration 2-6 hr, half-life 4 hr
Source page 43
Filter the extracted dose blocks for this individual drug.
Bronchospasm prophylaxis/ treatment
• Geriatric: PO 2 mg tid-qid, may in- crease gradually to 8 mg tid-qid
Candidate age grouping · source pages 42, 43